Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof of Concept Phase 2a Cohort Study

BACKGROUND: Chronic hepatitis C (HCV) genotype 4 (GT-4) represents up to 13% of HCV infections globally, concentrated in resource limited countries in the Middle East and Africa. In patients with HCV GT-1, the combination of ledipasvir and sofosbuvir has shown high cure rates with excellent tolerabi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Infect Dis
Hoofdauteurs: Kohli, Anita, Kapoor, Rama, Sims, Zayani, Nelson, Amy, Sidharthan, Sreetha, Lam, Brian, Silk, Rachel, Kotb, Colleen, Gross, Chloe, Teferi, Gebeyehu, Sugarman, Kate, Pang, Phillip S., Osinusi, Anu, Polis, Michael A., Rustgi, Vinod, Masur, Henry, Kottilil, Shyam
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4561573/
https://ncbi.nlm.nih.gov/pubmed/26187031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(15)00157-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items